Keysight Technologies KEYS

Reference table

1. What it is

Keysight Technologies (NYSE: KEYS) is the world's leading pure-play electronic design, emulation, and test-and-measurement company. Spun out of Agilent in 2014 (and originally the Hewlett-Packard test-and-measurement business founded in 1939), it sells the precision instruments and software used to design and validate electronics across communications, aerospace/defense, automotive/energy, semiconductor, and general electronics. Fiscal year ends October 31.

Two reporting segments (FY2024, latest full-year segmentation in the data):

• Communications Solutions Group (CSG) — $3.42B (69% of revenue): RF/microwave test, network test, EDA software, wireless/5G/6G, data-center and aerospace-defense test. This is the higher-growth engine; in Q2 FY26 CSG grew +35% YoY, led by +40% commercial communications and +24% aerospace/defense/government.
• Electronic Industrial Solutions Group (EISG) — $1.56B (31%): general-purpose lab and industrial instruments (multimeters, function generators, source-measure units), automotive/energy test, semiconductor parametric test, and board-assembly test. Q2 FY26 EISG grew +24% YoY with double-digit growth across all end markets.

Geographic revenue (FY2024): Americas $2.06B · Asia Pacific $1.99B · Europe $0.93B. Roughly balanced between the Americas and Asia — meaning meaningful exposure to Asian semiconductor/electronics capex and to US export-control and tariff policy (the Q2 filing details a $100M IEEPA tariff-refund receivable following a February 2026 Supreme Court ruling).

The strategic frame: Keysight is a software-and-services-enriched instrument company riding the secular complexity of 5G→6G, AI data-center networking, automotive electrification, and advanced-node semiconductors — but selling capital equipment whose order flow is inherently cyclical.

2. The expert thesis — why the panel is bullish (traceable)

There is no expert thesis to report. Keysight has zero coverage in the Synthos knowledge base — total_claims: 0, net_bullish_voices: 0, and an empty top array. No distilled voice, bullish or cautionary, has been ingested for this name.

What that means for this note (stated plainly): this verdict carries no conviction-track weight. It is built entirely from (a) reported FMP fundamentals, (b) live analyst consensus estimates, and (c) our own quant/valuation model. Nothing below cites a claim_id because there are none to cite — and per house standard we will never fabricate one. A reader should treat this as a rigorous fundamentals-and-quant read, not an expert-panel-corroborated conviction call. The absence of coverage is itself a reason the verdict lands at Watch rather than Buy.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.

Synthos fair value = the base case, ~$300 (−4%), with the full $210–$405 span as the honest range. Our base sits below the Street's $390 consensus because we (a) refuse to capitalize peak-cycle earnings at a peak-cycle multiple and (b) give zero conviction credit in the absence of any expert corroboration. Our bull ($405) roughly meets the Street high ($425); our bear ($210) is well below the Street low ($350) because the Street models are not underwriting a cyclical reversal. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). KEYS is a quality cyclical compounder with a genuine — but likely temporary — burst of acceleration:

• Forward growth: revenue CAGR FY25→FY28E ~15.3% ($5.38B → $8.24B); EPS (non-GAAP) CAGR ~20%+ as margins and buybacks lift the bottom line.
• Acceleration (the 2nd derivative) is positive right now but not durable: revenue growth is re-accelerating off the FY25 trough (FY25 +8% → FY26E +28% → FY27E +11% → FY28E +8%), and orders grew +56% YoY in Q2 FY26 ($2.05B) — a real inflection. But this is a cyclical upswing, not a secular one: consensus revenue and EPS fade back to high-single-digit growth by FY28 and estimates actually dip in FY29 ($11.18 EPS avg, on just 1 analyst). The acceleration is the good half of a cycle, not a new plateau.
• Room to run: the served T&M / EDA market is large but specialized; at $54B the law of large numbers plus a mature, oligopolistic niche caps the multibagger. A 3× from here implies a ~$160B T&M company — larger than the entire addressable niche can plausibly support at these multiples.
• Reinvestment runway: modest, high-return — capex is only ~2.4% of operating cash flow, R&D is ~19% of revenue, and the M&A engine (the $2B+ FY25 acquisition spend that lifted goodwill from $2.4B to $3.4B) is the main growth-supplement. Efficient, but not a hyperscale reinvestment story.

Exponential Potential: Low-Moderate (4/10). Own it for durable double-digit cyclical compounding, not for a fast multibagger — and be honest that today's acceleration is the flattering part of a cycle.

5. Financials (real numbers — FMP annual/quarterly)

• Revenue: FY25 (ended Oct 2025) $5.375B, +8.0% (FY24 $4.979B, which was −8.9% off FY23's $5.464B — a real cyclical dip and recovery). The business is clearly cyclical, not a straight-line compounder.
• Quarterly trajectory (the acceleration): Q1'25 $1.30B → Q2 $1.31B → Q3 $1.35B → Q4 $1.42B → Q1'26 $1.60B → Q2'26 $1.72B (+31.5% YoY). Orders hit $2.05B in Q2 FY26, +56% YoY — the leading indicator is inflecting hard.
• Margins: gross 63.7% TTM, EBITDA margin 23.7% TTM, operating ~18–20%, net 17.2% TTM. Software/services mix supports a structurally high gross margin for a hardware company.
• Earnings: FY25 GAAP net income $846M, GAAP EPS $4.90 (diluted $4.88). Note FY25 was depressed by acquisition/amortization; non-GAAP is materially higher — Q2 FY26 non-GAAP EPS was $2.87 vs $2.02 GAAP, and the forward estimates ($10–$13) are non-GAAP. Always mind the GAAP-vs-non-GAAP gap here.
• Cash flow: FY25 operating CF $1.41B, capex only −$128M, FCF $1.28B (FCF yield ~2.4% at this price). H1 FY26 free cash flow hit an all-time high per management.
• Balance sheet: total debt $2.97B, cash $1.87B, net debt just $1.10B → net-debt/EBITDA 0.24×. Interest coverage 10×. Financially about as sturdy as it gets. No dividend; capital return is via buybacks (~$377M repurchased FY25).

6. Valuation — priced in or room?

There is no way to call KEYS cheap: 52× trailing GAAP EPS, 8.9× sales, 37× EV/EBITDA, 8.6× book. FMP's own letter rating is B− with a price-to-earnings sub-score of 1/5 and price-to-book 1/5 — the model flags valuation as the weak link. The bull's defense is that non-GAAP EPS grows fast: forward P/E is ~31× (FY26E) → 27× (FY27E) → 24× (FY28E) — the multiple compresses as estimates climb. But two honest cautions: (1) those are non-GAAP estimates, flattering vs the 52× GAAP trailing; and (2) capitalizing peak-cycle earnings at ~30× is exactly how cyclicals become value traps at the top. A PEG of ~1.24 (trailing) rising to ~3.2 (forward) signals the easy multiple-vs-growth trade is gone. Street targets (context): consensus $390, high $425, low $350 — notably, even the Street low is above today's $314, i.e. the sell side sees the recent −6.5% drop as an entry, not a warning. We are more cautious: our ~$300 base FV is below consensus because we will not underwrite peak-cycle numbers at peak-cycle multiples with zero expert corroboration. Not a value buy; a quality-cyclical-at-a-full-price name to watch.

7. Technicals (from the tech block)

• Trend: mixed / cooling. $313.86 sits below the 50-DMA ($346.6) but comfortably above the 200-DMA ($254.4) — the intermediate trend has rolled over even as the longer trend stays up. MACD −2.16 (negative, momentum fading).
• Location: −15.9% off the 52-week high ($373.34), but +98% off the 52-week low ($158.51) — a huge 12-month run now in a pullback. Max drawdown from peak −15.9%.
• Momentum: RSI(14) 42 — neutral-to-soft, neither oversold nor overbought; the −6.5% one-day drop pushed it toward the lower half of the range.
• Relative strength: KEYS +90.8% 12-mo vs SPY +20.6% and QQQ +30.3% — enormous outperformance, but shorter windows are cooling (+8.3% 3-mo vs SPY +13.7% and QQQ +22.0% — now lagging both).
• Read: technicals say the momentum leadership is pausing after a near-double. Below the 50-DMA with a negative MACD and a fresh −6.5% gap, there is no technical urgency to buy; a base-building period or a test toward the 200-DMA (~$254) would offer a far better risk/reward entry — which is precisely the Watch stance.

8. Moat & competitive position

Keysight's moat is real and multi-layered: (1) technology leadership and precision at the leading edge of RF/microwave, high-speed digital, and network test — where being first to support a new standard (6G, PCIe/Ethernet speeds, new node characterization) wins the design-in; (2) switching costs and installed base — labs standardize on Keysight instruments, calibration, and software, and rip-and-replace is costly; (3) software/EDA attach that raises margin and stickiness; (4) scale in R&D (~$1B/yr, ~19% of sales) that smaller rivals can't match. The category is a rational oligopoly. The honest offset: it is capital equipment tied to customer capex cycles, so the moat protects share and margin but not the cyclicality of demand.

Peer set (FMP-supplied, market cap): Teradyne $57.8B (the closest test comp — semiconductor ATE), Teledyne $30.2B, Garmin $46.3B, plus contract-manufacturing/hardware names Celestica $38.7B, Flex $50.1B, Jabil $35.8B, HPE $54.6B, Ericsson $35.7B, Sandisk, and Super Micro. The truest comparables are Teradyne (ATE) and the broader electronic-instrument group; Keysight commands a premium multiple in the set, justified only if the current growth persists through the cycle.

9. Management, capital allocation & guidance

• Capital allocation: disciplined and shareholder-friendly — light capex (~2.4% of OCF), consistent buybacks (~$377M FY25), no dividend, and a bolt-on M&A engine (the ~$2B FY25 acquisition spend, which raised goodwill+intangibles to $4.7B — a watch item for future impairment if the cycle turns). Net-debt/EBITDA held at a conservative 0.24×.
• Insider activity: the sampled window shows a cluster of routine executive sales at these elevated prices — CEO Satish Dhanasekaran (multiple Form 4 sales, most recent 2026-06-30 at $361), CFO Neil Dougherty, and several SVPs/directors. These read as normal 10b5-1 diversification into strength rather than a red-flag signal, but the direction (selling, not buying, near the highs) is worth noting.
• Management's own guidance (half-weighted — their own book): the SEC 8-K earnings release (filed 2026-05-19, Q2 FY26) is a real earnings release and reads bullish. Management raised the full-year FY2026 outlook, citing "the strongest quarter in the company's history" and "accelerating demand." Specific dated guidance: Q3 FY26 revenue $1.730–$1.750B (midpoint ~+29% YoY) and Q3 FY26 non-GAAP EPS $2.43–$2.49 on ~173M diluted shares. This is management talking its own book at a cycle high — we half-weight it and note it corroborates the near-term acceleration but says nothing about cycle durability.

10. Catalysts & what to watch

• Next earnings: 2026-08-18 (Q3'26; Street EPS $2.46, right in management's $2.43–$2.49 guide; revenue ~$1.75B). The key lines: order growth (is +56% YoY sustaining or decelerating?) and CSG commercial-communications momentum.
• Order book / book-to-bill: the single most important cyclical tell — orders lead revenue by 1–3 quarters. A rollover here is the earliest warning.
• AI-networking & data-center test demand: the credible secular kicker inside a cyclical business — watch CSG commercial-communications mix.
• Semiconductor capex cycle: EISG semiconductor and Teradyne read-throughs signal the industrial half.
• M&A integration & goodwill: the $2B+ acquisition spend must earn its return; a cycle downturn raises impairment risk on the $4.7B goodwill+intangibles.
• Tariff / export policy: the IEEPA refund is a positive one-off; ongoing US-China export controls remain a swing factor for Asia revenue.

Thesis tripwires (what would change the call): two consecutive quarters of order deceleration; a book-to-bill below 1.0; a guidance cut; or non-GAAP margin compression. Conversely, a multiple de-rate toward ~25× on continued execution would flip this from Watch to Buy.

11. Key risks

• Cyclicality (structural, the main risk): demand tracks customer capex in comms, semis, and industrial — the booming order book today can deflate fast, and history shows it (FY24 revenue fell ~9%). At 52× trailing there is no valuation cushion for a downturn.
• Valuation / de-rating: 31× forward non-GAAP on peak-cycle earnings; any demand or margin wobble invites a sharp de-rate. FMP letter rating B− flags this.
• No expert corroboration: zero Synthos KB coverage means no independent conviction check — the call rests solely on fundamentals and quant.
• China / export-control & tariff exposure: significant Asia-Pacific revenue exposed to US-China policy; the IEEPA tariff situation cuts both ways.
• M&A / goodwill: $4.7B goodwill+intangibles from an active acquisition strategy — impairment risk if a bought-in business underperforms through a downturn.
• Insider selling into strength: a cluster of executive sales near the highs — likely routine, but not a buy signal.

12. Verdict, position sizing & monitoring

Watch. Keysight is a genuinely excellent, wide-moat, fortress-balance-sheet business (net-debt/EBITDA 0.24×, 64% gross margin, ROE 17%, FCF $1.28B) enjoying a real order-driven upcycle (orders +56% YoY, record H1, full-year raised). But three things hold us at Watch rather than Buy: (1) the stock trades at 52× trailing / 31× forward after a ~90% twelve-month run, capitalizing peak-cycle earnings at a peak-cycle multiple; (2) the business is structurally cyclical, and consensus already shows growth fading after FY28; and (3) there is zero expert coverage in the Synthos KB, so nothing corroborates a high-conviction call. Our base-case fair value (~$300) sits slightly below today's price and well below the Street's $390 — the sell side is buying the dip; we would rather wait.

• Sizing: if owned at all, satellite, ≤2%, and preferably scaled in on weakness (a base-build below the 50-DMA, or a test toward the 200-DMA ~$254) rather than chased at 52×.
• Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. A de-rate toward ~25× forward on sustained order growth would upgrade this to Buy — Tactical. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $313.86.
• Single biggest risk: a cyclical demand reversal that turns today's booming order book negative — with no valuation cushion to absorb it.

Provenance & disclosures

• Traceability: 0 KB claims, breadth 0 — Keysight has no expert coverage in the Synthos knowledge base. This note cites no claim_ids because none exist; per house standard, conviction is never fabricated. The verdict is explicitly fundamentals- and quant-driven.
• Data as-of: fundamentals 2026-04-30 (Q2 FY26) · estimates & prices 2026-07-03 · no expert claims. Forward figures are analyst consensus (FMP) and are labeled as estimates; note the estimate stream is non-GAAP EPS while trailing P/E is GAAP.
• Management caveat: the Q2 FY26 8-K guidance (raised FY26 outlook; Q3 rev $1.73–1.75B, EPS $2.43–2.49) is management's own book, half-weighted by design and captured at a cycle high.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").